Wed, Mar 26, 4:10 PM, Zacks ARIAD Candidate in Phase II Study - Analyst Blog ARIAD started phase II pivotal study on AP26113 for non-small cell lung cancer (NSCLC) in patients who had previously been treated with Pfizer's Xalkori (crizotinib).
ARIAD Pharmaceuticals is engaged in the development and commercialization of small-molecule drugs to treat cancer patients. Co.'s commercial product is Iclusig™ (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to other TKI therapies. Co. also has two other product candidates in development: AP26113, which is being studied in patients with advanced solid tumors including non-small cell lung cancer; and ridaforolimus, which is being studied in patients with various types of cancers.
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20
minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.